Artificially Sweetened Beverage Consumption Is Positively Associated with Newly Diagnosed Diabetes in Normal-Weight but Not in Overweight or Obese Brazilian Adults by Yarmolinsky, James et al.
The Journal of Nutrition
Nutritional Epidemiology
Artificially Sweetened Beverage Consumption
Is Positively Associated with Newly Diagnosed
Diabetes in Normal-Weight but Not in
Overweight or Obese Brazilian Adults1–3
James Yarmolinsky,4 Bruce B Duncan,4,5* Lloyd E Chambless,6 Isabela M Bensenor,7,8 Sandhi M Barreto,9
Alessandra C Goulart,7,8 Itamar S Santos,7,8 Maria de Fa´tima Sander Diniz,9 and Maria Ineˆs Schmidt4,5
4Postgraduate Program in Epidemiology, School of Medicine and Hospital de Clı´nicas de Porto Alegre, Federal University of Rio Grande
do Sul, Porto Alegre, Brazil; 5Department of Epidemiology, and 6Department of Biostatistics, University of North Carolina, Chapel Hill,
NC; 7Department of Clinical Medicine, Faculty of Medicine and 8Center for Clinical and Epidemiological Research, University Hospital,
University of Sa˜o Paulo, Sa˜o Paulo, Brazil; and 9Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
Abstract
Background: Recent animal studies suggest that artificially sweetened beverage (ASB) consumption increases diabetes risk.
Objective:We examined the relation of ASB intake with newly diagnosed diabetes andmeasures of glucose homeostasis
in a large Brazilian cohort of adults.
Methods: We used cross-sectional data from 12,884 participants from the Brazilian Longitudinal Study of Adult Health
(ELSA-Brasil). ASB use was assessed by questionnaire and newly diagnosed diabetes by a 2-h 75-g oral glucose tolerance
test and/or glycated hemoglobin. Logistic and linear regression analyses were performed to examine the association of
ASB consumption with diabetes and continuous measures of glucose homeostasis, respectively.
Results: Although ASB consumption was not associated with diabetes in logistic regression analyses after adjustment for
body mass index (BMI; in kg/m2) overall, the association varied across BMI categories (P-interaction = 0.04). Among those
with a BMI <25, we found a 15% increase in the adjusted odds of diabetes for each increase in the frequency of ASB
consumption per day (P = 0.001); compared with nonusers, ASB users presented monotonic increases in the adjusted ORs
(95% CIs) of diabetes with increased frequency of consumption: 1.03 (0.60, 1.77), 1.43 (0.93, 2.20), 1.62 (1.08, 2.44), and 2.51
(1.40, 4.50) for infrequent, 1–2, 3–4, and >4 times/d, respectively. In linear regression analyses, among normal-weight
individuals, greater ASB consumption was also associated with increased fasting glucose concentrations (P = 0.01) and poorer
b-cell function (P= 0.009). No such associationswere seen for thosewith BMI$25. In fact, in overweight or obese participants,
greater ASB consumption was significantly associated with improved indexes of insulin resistance and 2-h postload glucose.
Conclusions:Normal-weight, but not excess-weight, individuals with greater ASB consumption presented diabetesmore
frequently and had higher fasting glucose and poorer b-cell function. J Nutr 2016;146:290–7.
Keywords: type 2 diabetes, artificially sweetened beverage consumption, BMI, glucose intolerance, b-cell function
Introduction
Consumption of artificial sweeteners in the United States in-
creased from near zero in the 1960s to about 15% of individuals
in 2003–2004 (1). By 2007–2008, NHANES data suggest that
approximately one-third of the adult population regularly
consumed low-calorie sweeteners and that 22% of normal-
weight individuals did so (2). Perhaps owing to the perceived
status as a healthy alternative to sugar-sweetened beverages and
foods, consumption of low-calorie sweeteners has not been
limited solely to those with a disease such as diabetes or
obesity but has been adopted more broadly as a healthy habit.
Recently, animal experiments have suggested that artificial
noncaloric sweeteners may contribute to glucose intolerance
through alterations of the composition and function of intestinal
microbiota, which may in turn upregulate de novo glucose
synthesis pathways by the host (3).
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Evidence from human studies concerning health benefits of
artificial sweeteners is inconsistent (4, 5). Some studies link
higher consumption of artificially sweetened beverages (ASBs)10
with weight gain, metabolic dysfunction, and elevated risk of
type 2 diabetes (6–9), independently of baseline BMI (in kg/m2)
(9–11). Others report nonsignificant associations after adjust-
ment for BMI (12–16). Recently, it has been reported that
substitution for sugar-sweetened beverages by water or non-
sweetened coffee or tea reduces the risk of developing diabetes,
but substitution by ASBs does not (16). Few epidemiologic
studies have assessed the potential effect modification by BMI of
the ASB-diabetes association. Moreover, few epidemiologic
studies have examined the association of regular ASB consump-
tion with measures of glucose homeostasis, which can help
identify the putative mechanisms through which ASBs may
affect diabetes development (9, 17).
In light of the inconsistent evidence that ASBs may increase
the risk of diabetes and other conditions that they are intended
to prevent and of the relative paucity of epidemiologic literature
on this association across the different strata of BMI, further
examination is warranted of the association of regular ASB
consumption with both diabetes and markers of the underlying
pathophysiologic processes. Thus, we studied the association of
ASB consumption with newly diagnosed diabetes, intermediate
hyperglycemia, and underlying laboratory measurements related
to glucose homeostasis.
Methods
Study design and population. The Brazilian Longitudinal Study of
Adult Health (in Portuguese, Estudo Longitudinal de Sau´de do Adulto–
Brasil or ELSA-Brasil) is a cohort study designed to identify risk factors
for diabetes and cardiovascular disease. The details of the study,
including design, eligibility criteria, sources and methods of recruitment,
and measurements obtained, have been described in detail elsewhere
(18). The cohort comprises 15,105 civil servant volunteers, aged 35–74 y
at baseline (2008–2010), who were sampled from universities or re-
search institutions located in 6 cities of 3 different regions in Brazil. All
currently active employees of the selected institutions and those retired
but living within the metropolitan area of the study centers were eligible;
individuals were excluded for pregnancy, mental incapacity, or major
diseases such as terminal cancer that severely limited the projected life
span. All data for the current cross-sectional analyses were collected at
baseline. The study was approved by the local research and ethics
committees of all involved institutions.
For the current investigation, we excluded those with known diabetes
(participants who reported having been previously diagnosed with
diabetes by a physician and/or using diabetes medication in the 2
previous weeks; n = 1473) from all analyses. We also excluded
participants with missing data at baseline for the following variables:
BMI (n = 6), waist-hip ratio (n = 8), race/skin color (n = 184), beverage
consumption (n = 55), current smoking status (n = 1), hypertension
(n = 13), leisure time physical activity (n = 221), dietary changes in
previous 6 mo (n = 45), total energy intake (n = 36), and laboratory
measurements (n = 362). Some participants had missing data for $2
variables. Consequently, our main analyses were performed on 12,884
participants.
Exposure assessment. ASB intake was assessed at the baseline
examination through a validated 114-item food-frequency questionnaire
(19). Participants were asked to provide information on their typical
eating habits, including attempts to modify their diet, in the 6 months
before the baseline examination of the ELSA-Brasil. For assessment of
beverage intake specifically, participants were asked to provide both
the typical frequency with which they consumed ASBs (>3 times/d,
2–3 times/d, 1 time/d, 5–6 times/wk, 2–4 times/wk, 1 time/wk, 1–3 times/mo,
never/almost never) and the typical quantity of the beverage consumed
on each occasion in relation to a reference cup size. Possible types of
beverage were soda, coffee, tea, natural juice (which is frequently
sweetened in Brazil), reconstituted natural juice, and fruit-flavored
drinks (e.g., Tang, Kool-Aid, or Crystal Light/Clight). Participants who
consumed these beverages were further asked to specify whether each
beverage was typically sugar sweetened (if sugar was an ingredient in the
beverage and/or an individual manually added sugar to the beverage),
artificially sweetened (if an artificial sweetener was an ingredient in the
beverage and/or an individual manually added artificial sweetener—in
either a liquid or a solid form—to the beverage), or unsweetened when
consumed. Last, for secondary analyses, intakes of diet and ‘‘light’’ foods,
which can contain artificial sweetener—including yogurt, ice cream,
popsicles, caramel candy, gelatin desserts, chocolate, pudding/mousse,
jam, and cereal bars—were examined in a similar manner.
Outcome ascertainment. A 12-h fasting blood sample was drawn by
venipuncture soon after each participant arrived at the baseline clinic
visit. A 2-h 75-g oral-glucose-tolerance test was then administered to
participants without known diabetes. Glucose was measured by the
hexokinase method (ADVIA Chemistry; Siemens), glycated hemoglobin
(HbA1C) was measured using high-pressure liquid chromatography
(Bio-Rad Laboratories), a National Glycohemoglobin Standardization
Program certified method, and insulin was measured with an immu-
noenzymatic assay (ELISA) (Siemens).
Diabetes was classified according to blood glucose measurements.
Specifically, a participant was defined as having newly diagnosed
diabetes if he or she reached the threshold for fasting plasma glucose
($126 mg/dL), 2-h postload plasma glucose ($200 mg/dL), or HbA1c
($6.5%; 48 mmol/mol) (20, 21). Given the age range of our participants
and the fact that none were using medications, most of these newly
diagnosed cases will have type 2 diabetes.
Impaired glucose tolerance (IGT) was defined as a 2-h postload
glucose concentration $140 mg/dL and <200 mg/dL, impaired fasting
glucose (IFG) as a fasting glucose concentration $100 mg/dL and <126
mg/dL (20, 21), and elevated HbA1c as a value $5.7% (39 mmol/mol)
and <6.5% (48 mmol/mol) in individuals not otherwise classified as
having diabetes (22).
HOMA-IR was defined as the product of fasting glucose (in mmol/L)
and insulin concentrations (mIU/mL) divided by 22.5, and HOMA b-cell
function (HOMA-b) was defined as the product of 20 and fasting insulin
(mIU/mL) divided by fasting glucose (mmol/L) minus 3.5 (23). Compos-
ite insulin sensitivity index (ISI-composite), as proposed by DeFronzo
and Matsuda (24), was calculated as 10,000 divided by the square
root of the product of fasting and 2-h postload glucose and insulin
concentrations.
Covariate assessment. A comprehensive set of questionnaires, tests,
and measurements was carried out (25). Blood pressure was measured
using an oscillometric method (HEM 705CP; Omron). Waist-hip ratio
was calculated as the ratio of measured waist to measured hip
circumference.
Statistical analyses. Baseline characteristics of the sample were
summarized using unadjusted means and SDs for continuous variables
and frequencies and percentages for categorical variables, according to
ASB intake categories [nonuser (<1 time/wk; referent category), infre-
quent (at least 1 time/wk but <1 time/d), 1–2 times/d, 3–4 times/d,
>4 times/d]. Because quantity of ASB typically consumed on each occasion
did not differ markedly by frequency of ASB consumption, analyses were
performed using just the frequency of ASB consumption.
Multiple linear regression was performed to assess the association
between category of ASB intake and continuous measures of fasting
glucose, 2-h postload glucose, HbA1c, and the indexes HOMA-IR,
10 Abbreviations used: ASB, artificially sweetened beverage; ELSA-Brasil,
Estudo Longitudinal de Sau´de do Adulto–Brasil; HbA1C, glycated hemoglobin;
HOMA-b, homeostasis model assessment of b-cell function; IFG, impaired
fasting glucose; IGT, impaired glucose tolerance; ISI-composite, composite
insulin sensitivity index.
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HOMA-b, and ISI-composite. Multivariable logistic regression was
performed to generate ORs and 95%CIs for the association of categories
of ASB intake with newly diagnosed diabetes. After exclusion of cases of
newly diagnosed diabetes (n = 1426), we also analyzed ASB associations
with states of intermediate hyperglycemia (IFG, IGT, and HbA1c
$5.7%, <6.5%) in the remaining 11,458 participants. In secondary
analyses, multivariable logistic regression was also performed to
examine the association of diet or ‘‘light’’ food intake (using the same
categories of consumption as for ASBs) with diabetes and measures of
intermediate hyperglycemia. To control for confounding, we selected
established risk factors for diabetes and factors known to be associated
with ASB consumption, based on prior studies and theoretical consider-
ations, as follows: sex, age (y), race/skin color, study center, educational
attainment, current smoking status, leisure time physical activity,
hypertension, family history of diabetes, dietary changes in previous
6 mo, alcohol consumption (g/d), sugar-sweetened beverage consump-
tion, unsweetened beverage consumption, diet/light food consumption,
total energy intake (kcal/d), BMI, and waist-to-hip ratio.
In modeling, interaction terms were used to investigate whether
associations differed by sex, age (<51, $51 y; median cutoff), or BMI
(<25, $25 to <30, $30). Although the <25 group includes participants
with both ‘‘normal’’ and ‘‘underweight’’ BMI classifications, only
130 (2.6%) participants in this group were deemed to be in the
‘‘underweight’’ classification, and thus this group is referred to as
‘‘normal weight’’ in the text. All statistical tests were 2-sided and
significance was defined at P < 0.05. Statistical analyses were performed
with SAS 9.4 (SAS Institute, Inc.).
Results
Baseline descriptive data of ELSA-Brasil participants by
frequency of ASB consumption are presented in Table 1.
Approximately 33% of participants reported consuming ASBs at
least 1 time/d,;15% (1934) reported consuming ASBs 3–4 times/d,
and;5% (644) reported consumption of >4 times/d. Artificially
sweetened coffee was consumed by 59.6% of those reporting
ASBs consumption, diet soda by 54.1%, artificially sweetened
natural juice by 32.3%, tea by 26.7%, artificially sweet-
ened reconstituted fruit juice by 23.8%, and artificially sweetened
fruit-flavored drinks by 10.5%. When considering frequencies
of consumption of these beverages, total ASB consumption in the
sample was mainly accounted for by addition of artificial
sweeteners to coffee (62.0%), followed by consumption of diet
soda (12.7%), artificially sweetened natural juice (10.2%), tea
(7.2%), artificially sweetened reconstituted fruit juice (5.4%),
and artificially sweetened fruit-flavored drinks (2.5%). Gener-
ally, those with greater use of ASBs, compared with nonusers,
were more likely to have reported modifying their diet in the
previous 6 mo, had a higher BMI, and were more likely to
have hypertension and a family history of diabetes.
At baseline, we found 1426 cases of newly diagnosed diabetes,
7,556 cases of IFG, and 2,965 cases of IGT.
In a model adjusted for age, sex, race, and study center, ASB
consumption was significantly associated with odds of newly
diagnosed diabetes among those consuming ASBs 1–2 times/d
(OR: 1.35; 95%CI: 1.14, 1.59), 3–4 times/d (OR: 1.27; 95%CI:
1.08, 1.49), and >4 times/d (OR: 1.54; 95% CI: 1.21, 1.95)
compared with nonusers (P < 0.0001) (Table 2). This association
became nonsignificant after further adjustment for sociodemo-
graphic, lifestyle, and dietary variables, most notably after
adding BMI and waist-to-hip ratio (P = 0.14). ASB consumption
was significantly associated with odds of impaired fasting
TABLE 1 Characteristics of ELSA-Brasil participants without a previous diabetes diagnosis by frequency
of ASB consumption per day at baseline (2008–2010)1
Characteristic
Total sample
(n = 12,884)
Nonusers
(n = 7702)
Infrequent
(n = 902)
1–2 times/d
(n = 1702)
3–4 times/d
(n = 1934)
.4 times/d
(n = 644)
ASB intake, occasions/d 0.95 6 1.60 0.00 6 0.02 0.30 6 0.14 1.22 6 0.47 3.24 6 0.65 5.51 6 1.08
Coffee 0.59 6 1.17 0.00 6 0.00 0.01 6 0.07 0.48 6 0.47 2.41 6 1.18 3.20 6 1.12
Soda 0.12 6 0.40 0.00 6 0.01 0.19 6 0.18 0.24 6 0.35 0.28 6 0.67 0.65 6 1.00
Natural juice 0.10 6 0.37 0.00 6 0.00 0.03 6 0.11 0.19 6 0.32 0.23 6 0.56 0.68 6 1.00
Other beverages2 0.14 6 0.47 0.00 6 0.01 0.07 6 0.13 0.31 6 0.41 0.32 6 0.65 0.98 6 1.22
Women 7057 (54.8) 3794 (49.3) 547 (60.6) 1066 (62.6) 1261 (65.2) 389 (60.4)
Age, y 51.5 6 8.9 51.1 6 8.9 51.4 6 9.0 51.8 6 9.2 52.6 6 8.9 52.6 6 8.6
Race/color
Black 1983 (15.4) 1361 (17.7) 111 (12.3) 209 (12.3) 230 (11.9) 72 (11.2)
Mixed ``Pardo ` ` 3620 (28.1) 2363 (30.7) 201 (22.3) 423 (24.8) 455 (23.5) 178 (27.6)
White 6855 (53.2) 3719 (48.3) 564 (62.5) 1007 (59.2) 1186 (61.3) 379 (58.9)
Other3 426 (3.3) 259 (3.3) 26 (2.9) 63 (3.7) 63 (3.3) 15 (2.3)
Low educational attainment4 5034 (39.1) 3578 (46.5) 262 (29.0) 488 (28.7) 545 (28.2) 161 (25.0)
Current smoker 1702 (13.2) 1141 (14.8) 88 (9.8) 156 (9.2) 213 (11.0) 104 (16.2)
Total energy intake, kcal/d 2964 6 1230 2964 6 1219 2972 6 1200 2952 6 1278 2986 6 1260 2921 6 1178
Low physical activity5 10720 (83.2) 6516 (84.6) 741 (82.2) 1368 (80.4) 1560 (80.7) 535 (83.1)
Hypertension 4205 (32.6) 2424 (31.5) 283 (31.4) 562 (33.0) 703 (36.4) 233 (36.2)
Family history of diabetes 4661 (36.2) 2648 (34.4) 326 (36.1) 643 (37.8) 773 (40.0) 271 (42.1)
Modified diet in previous 6 mo 3798 (29.5) 1853 (24.1) 314 (34.8) 634 (37.2) 720 (37.2) 277 (43.0)
BMI, kg/m2 26.8 6 4.6 26.1 6 4.5 27.1 6 4.7 27.7 6 4.6 27.7 6 4.7 28.4 6 4.9
WHR 0.89 6 0.09 0.89 6 0.09 0.89 6 0.09 0.89 6 0.09 0.89 6 0.09 0.90 6 0.09
1 Values are means 6 SEMS or n (%). ASB, artificially sweetened beverage; ELSA-Brasil, Estudo Longitudinal de Sau´de do Adulto–Brasil;
WHR, waist-to-hip ratio.
2 ‘‘Other beverages’’: reconstituted natural juice, fruit-flavored drinks, and tea.
3 ‘‘Other’’: those reporting their race/skin color as ‘‘Asian’’ or ‘‘indigenous.’’
4 Highest level of instruction completed was high school or less.
5 Typically engage in leisure time physical activity 1 d/wk or less.
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glucose in both the minimally adjusted model and a model
adjusting for all covariates (OR: 1.27; 95% CI: 1.02, 1.59
among those consuming ASBs >4 times/d compared with
nonusers in the fully adjusted analysis; P = 0.03). ASB
consumption was also significantly inversely associated with
odds of impaired glucose tolerance in both the minimally
adjusted and fully adjusted models (OR: 0.68; 95% CI: 0.54,
0.87 among those consuming ASBs >4 times/d compared with
nonusers in the fully adjusted analysis; P = 0.005). No
association was found when we examined ASB consumption
with intermediate hyperglycemia as assessed byHbA1c ($5.7%,
<6.5%) in either model (P$ 0.69, for both). Analyses modeling
ASB consumption in a continuous fashion, also seen in Table 2,
showed similar results as those modeling ASB consumption in a
categorical fashion.
Tests for heterogeneity in the association of ASB consumption
with newly diagnosed diabetes identified evidence for interaction
by BMI strata (P-interaction = 0.04). In fully adjusted analyses
stratified by BMI (<25, $25 to <30, $30), we found a graded
positive risk relation between ASB consumption and type 2
diabetes in normal-weight participants among those consuming
ASBs infrequently (OR: 1.03; 95% CI: 0.60, 1.77), 1–2 times/d
(OR: 1.43; 95% CI: 0.93, 2.20), 3–4 times/d (OR: 1.62; 95% CI:
1.08, 2.44), and >4 times/d (OR: 2.51; 95% CI: 1.40, 4.50)
comparedwith nonusers but no association in either overweight or
obese participants (Table 3 and Supplemental Table 1). Likewise,
ASB consumption was associated with a borderline significantly
increased risk of IFG in normal-weight individuals (P = 0.07),
whereas no association was found in overweight and obese strata
in either minimal or fully adjusted models. In contrast, in fully
adjusted analyses, increased consumptionwas inversely associated
with the adjusted odds of IGTamong those in the overweight BMI
stratum among those consuming ASBs infrequently (OR: 1.03;
95% CI: 0.80, 1.34), 1–2 times/d (OR: 1.09; 95% CI: 0.88, 1.35),
3–4 times/d (OR: 0.89; 95% CI: 0.72, 1.11), and >4 times/d
(OR: 0.56; 95% CI: 0.39, 0.81) compared with nonusers,
whereas no association was found for those in either normal-
weight or obese strata.
When we analyzed associations of ASB consumption with
these outcomes in a continuous fashion, which depicts the
association as a linear trend, similar associations were observed.
Among normal-weight individuals, in a fully adjusted model, we
found a 15% (OR: 1.15; 95% CI: 1.06, 1.26; P = 0.001)
increased odds of type 2 diabetes and a 7% (OR: 1.07; 95% CI:
1.01, 1.13; P = 0.01) increased odds of IFG with each additional
ASB consumed daily (Table 3). Likewise, we found a 0.43 mg/dL
increase in fasting glucose concentrations (P = 0.01) and a
0.77% decrease in HOMA-b (P = 0.009), a measure of b-cell
function, for each additional frequency of daily ASB consump-
tion (Table 4). Within the overweight stratum, each increase in
daily ASB consumption was associated with a 7% (OR: 0.93,
95% CI: 0.89, 0.98; P = 0.008) decrease in the adjusted odds of
IGT. Each additional ASB consumption for individuals in the
overweight stratum was also associated with a 0.14 increase in
ISI-composite score in adjusted analyses (P = 0.02), indicative of
enhanced insulin sensitivity. For individuals in the obese
stratum, each increase in daily ASB consumption was associated
with a 0.19 change in ISI-composite score (P = 0.0002); however,
no associations with any measures of blood glucose concentra-
tion were seen. Small, positive associations were noted between
ASB consumption and glycated hemoglobin concentrations
among both normal-weight and overweight participants, al-
though these changes did not appear to be clinically significant.
There was no evidence for interaction in the ASB association
with newly diagnosed diabetes by age or sex. In analyses
stratified by type of beverage, a greater prevalence of newly
diagnosed diabetes in normal-weight individuals was seen both
when the ASB was mostly coffee (defined as individuals who
reported greater total consumption of artificially sweetened
coffee than all other ASBs; OR: 1.14; 95% CI: 1.03, 1.27) and
TABLE 2 Adjusted ORs (95% CIs) for the association of ASB consumption with newly diagnosed diabetes and measures of
intermediate hyperglycemia: ELSA-Brasil (2008–2010), n = 12,8841
Nonusers Infrequent 1–2 times/d 3–4 times/d .4 times/d P value2
For a one unit change
in frequency of ASB
consumption/d P value3
Newly diagnosed diabetes
Total, n 7702 902 1702 1934 644 12,884
Cases, n 810 77 214 232 93 1426
Model 1 1.00 0.88 (0.69, 1.14) 1.35 (1.14, 1.59) 1.27 (1.08, 1.49) 1.54 (1.21, 1.95) ,0.0001 1.08 (1.04, 1.11) ,0.0001
Model 2 1.00 0.82 (0.63, 1.07) 1.16 (0.96, 1.41) 1.07 (0.88, 1.30) 1.23 (0.94, 1.62) 0.14 1.03 (0.98, 1.07) 0.21
Impaired fasting glucose
Total, n 6892 825 1488 1702 551 11,458
Cases, n 4466 537 993 1169 391 7556
Model 1 1.00 1.13 (0.96, 1.32) 1.24 (1.09, 1.40) 1.35 (1.20, 1.52) 1.46 (1.20, 1.78) ,0.0001 1.07 (1.04, 1.10) ,0.0001
Model 2 1.00 1.04 (0.88, 1.23) 1.12 (0.97, 1.29) 1.23 (1.07, 1.42) 1.27 (1.02, 1.59) 0.03 1.04 (1.01, 1.07) 0.02
Impaired glucose tolerance
Total, n 6892 825 1488 1702 551 11,458
Cases, n 1725 216 438 457 129 2965
Model 1 1.00 1.10 (0.93, 1.31) 1.30 (1.14, 1.48) 1.11 (0.98, 1.26) 0.92 (0.75, 1.14) 0.001 1.00 (0.98, 1.03) 0.75
Model 2 1.00 0.98 (0.82, 1.16) 1.07 (0.93, 1.24) 0.90 (0.78, 1.04) 0.68 (0.54, 0.87) 0.005 0.94 (0.91, 0.97) 0.001
1 Values are ORs (95% CIs) unless otherwise indicated. Adjusted through logistic regression for the following covariates—model 1: adjusted for sex, age (y), race/skin color, and
study center. Model 2: model 1 plus educational attainment, current smoking status, leisure time physical activity, hypertension, family history of diabetes, dietary changes in
previous 6 mo, alcohol consumption, sugar-sweetened beverage consumption, unsweetened beverage consumption, diet/light food consumption, total energy intake, BMI, and
waist-to-hip ratio. For impaired fasting glucose and impaired glucose tolerance analyses, n = 11,458 after exclusion of participants with newly diagnosed diabetes. ASB, artificially
sweetened beverage; ELSA-Brasil, Estudo Longitudinal de Sau´de do Adulto–Brasil.
2 P value represents the test for an overall association of frequency of ASB consumption per day with each respective outcome of interest.
3 P value represents the test for the association of an increase in frequency of one additional moment of ASB consumption per day with each respective outcome of interest.
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TABLE 3 Adjusted ORs (95% CIs) for the association of ASB consumption with newly diagnosed diabetes and measures of
intermediate hyperglycemia, stratified by BMI category: ELSA-Brasil (2008–2010), n = 12,8841
BMI category,
kg/m2 Nonusers Infrequent 1–2 /d 3–4 /d .4 /d P value2
For a one unit change
in frequency of ASB
consumption/d P value3
Newly diagnosed diabetes4
BMI ,25
Total, n 3440 329 504 570 155 4998
Cases, n 194 17 35 47 20 313
Model 1 1.00 1.07 (0.64, 1.80) 1.45 (0.99, 2.14) 1.77 (1.25, 2.51) 2.88 (1.72, 4.81) ,0.0001 1.19 (1.11, 1.28) ,0.0001
Model 2 1.00 1.03 (0.60, 1.77) 1.43 (0.93, 2.20) 1.62 (1.08, 2.44) 2.51 (1.40, 4.50) 0.02 1.15 (1.06, 1.26) 0.001
BMI $25 to ,30
Total, n 2922 381 753 846 283 5185
Cases, n 336 27 87 84 33 567
Model 1 1.00 0.65 (0.43, 0.98) 1.07 (0.83, 1.39) 0.90 (0.70, 1.18) 1.04 (0.71, 1.54) 0.25 1.00 (0.94, 1.05) 0.86
Model 2 1.00 0.69 (0.45, 1.06) 1.14 (0.85, 1.54) 1.02 (0.75, 1.39) 1.13 (0.73, 1.75) 0.34 1.01 (0.95, 1.09) 0.68
BMI $30
Total, n 1340 192 445 518 206 2701
Cases, n 280 33 92 101 40 546
Model 1 1.00 0.84 (0.56, 1.26) 1.06 (0.80, 1.39) 0.94 (0.73, 1.23) 0.98 (0.67, 1.44) 0.87 0.99 (0.94, 1.05) 0.84
Model 2 1.00 0.83 (0.55, 1.26) 0.97 (0.71, 1.33) 0.85 (0.62, 1.16) 0.90 (0.58, 1.40) 0.80 0.97 (0.91, 1.04) 0.44
Impaired fasting glucose4
BMI ,25
Total, n 3246 312 469 523 135 4685
Cases, n 1819 169 260 300 82 2630
Model 1 1.00 1.02 (0.80, 1.30) 1.17 (0.95, 1.44) 1.28 (1.06, 1.57) 1.40 (0.97, 2.02) 0.04 1.06 (1.02, 1.11) 0.006
Model 2 1.00 0.98 (0.76, 1.26) 1.17 (0.94, 1.46) 1.32 (1.06, 1.65) 1.48 (1.00, 2.19) 0.07 1.07 (1.01, 1.13) 0.01
BMI $25 to ,30
Total, n 2586 354 666 762 250 4618
Cases, n 1833 242 472 534 180 3261
Model 1 1.00 1.00 (0.78, 1.29) 1.08 (0.89, 1.32) 1.05 (0.87, 1.26) 1.12 (0.83, 1.51) 0.90 1.01 (0.97, 1.05) 0.76
Model 2 1.00 1.00 (0.77, 1.29) 1.12 (0.90, 1.40) 1.10 (0.88, 1.36) 1.16 (0.83, 1.62) 0.80 1.01 (0.96, 1.06) 0.72
BMI $30
Total, n 1060 159 353 417 166 2155
Cases, n 814 126 261 335 129 1665
Model 1 1.00 1.20 (0.79, 1.84) 0.91 (0.68, 1.22) 1.26 (0.94, 1.69) 1.08 (0.72, 1.62) 0.38 1.03 (0.97, 1.10) 0.32
Model 2 1.00 1.23 (0.79, 1.90) 0.94 (0.68, 1.32) 1.27 (0.90, 1.80) 1.13 (0.71, 1.81) 0.46 1.04 (0.97, 1.12) 0.30
Impaired glucose tolerance4
BMI ,25
Total, n 3246 312 469 523 135 4685
Cases, n 566 51 89 91 15 812
Model 1 1.00 0.99 (0.72, 1.37) 1.20 (0.93, 1.55) 1.06 (0.83, 1.37) 0.62 (0.36, 1.08) 0.26 0.97 (0.92, 1.03) 0.39
Model 2 1.00 0.97 (0.70, 1.34) 1.07 (0.81, 1.43) 0.99 (0.74, 1.32) 0.54 (0.30, 0.98) 0.30 0.94 (0.88, 1.01) 0.10
BMI $25 to ,30
Total, n 2586 354 666 762 250 4618
Cases, n 739 104 207 209 50 1309
Model 1 1.00 1.10 (0.85, 1.41) 1.14 (0.94, 1.38) 0.92 (0.76, 1.11) 0.60 (0.43, 0.84) 0.008 0.95 (0.91, 0.99) 0.01
Model 2 1.00 1.03 (0.80, 1.34) 1.09 (0.88, 1.35) 0.89 (0.72, 1.11) 0.56 (0.39, 0.81) 0.01 0.93 (0.89, 0.98) 0.008
BMI $30
Total, n 1060 159 353 417 166 2155
Cases, n 420 61 142 157 64 844
Model 1 1.00 0.89 (0.63, 1.26) 0.99 (0.77, 1.28) 0.86 (0.68, 1.10) 0.89 (0.63, 1.26) 0.74 0.96 (0.91, 1.01) 0.11
Model 2 1.00 0.89 (0.62, 1.28) 0.96 (0.72, 1.29) 0.81 (0.60, 1.08) 0.86 (0.58, 1.28) 0.64 0.94 (0.88, 1.00) 0.06
1 Values are ORs (95% CIs) unless otherwise indicated. Adjusted through logistic regression for the following covariates—model 1: adjusted for sex, age (y), race/skin color, and
study center. Model 2: model 1 plus educational attainment, current smoking status, leisure time physical activity, hypertension, family history of diabetes, dietary changes in
previous 6 mo, alcohol consumption, sugar-sweetened beverage consumption, unsweetened beverage consumption, diet/light food consumption, total energy intake, BMI, and
waist-to-hip ratio. For impaired fasting glucose and impaired glucose tolerance analyses, n = 11,458 after exclusion of participants with newly diagnosed diabetes. ASB, artificially
sweetened beverage; ELSA-Brasil, Estudo Longitudinal de Sau´de do Adulto–Brasil.
2 P value represents the test for an overall association of frequency of ASB consumption per day with each respective outcome of interest.
3 P value represents the test for an association of an increase in frequency of one additional moment of ASB consumption per day with each respective outcome of interest.
4 Tests for interaction by BMI category, model 2: newly diagnosed diabetes, P-interaction = 0.04; impaired fasting glucose, P-interaction = 0.83; impaired glucose tolerance,
P-interaction = 0.51.
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when it was mostly beverages other than coffee (OR: 1.21; 95%
CI: 1.08, 1.35) for each increase in ASB consumption per day
(Supplemental Tables 2–5). Last, in secondary analyses (data not
shown), no association of ‘‘low-calorie’’ and ‘‘diet’’ foods with
diabetes, IFG, or IGTwas found in minimally and fully adjusted
overall analyses (P $ 0.15 for all outcomes) or in analyses
stratified by BMI (P $ 0.13 for all outcomes).
Discussion
Our finding of an overall null association of ASB consumption
with newly diagnosed diabetes when adjusting for baseline
adiposity is consistent with the results from 3 previous cohort
analyses (12–14).Two previous prospective studies, the Multi-
Ethnic Study of Atherosclerosis and French Prospective Etude
Epide´miologique aupre`s des femmes de la Mutuelle Ge´ne´rale de
l’Education Nationale, the latter with 14 y of follow-up, did find
that daily users of diet soda and ASBs, respectively, had an
increased risk of type 2 diabetes, even after adjusting for baseline
adiposity (9, 10).
One might suspect that our discordant findings of greater
odds of newly diagnosed diabetes, IFG, and poorer b-cell
function in normal-weight individuals but not in those with
excess weight result from chance. However, results of the 3
previous studies that presented analyses stratified by baseline
BMI category, all with incident outcomes, when taken together
show greater risk in normal-weight individuals. In the Multi-
Ethnic Study of Atherosclerosis, with a smaller number of cases,
a somewhat higher but nonsignificant risk was found for
normal-weight participants (HR: 1.94; 95% CI: 0.87, 4.35)
than in those with excess weight (HR: 1.54; 95% CI: 1.15,
2.07). In the European Prospective Investigation into Cancer and
Nutrition–InterAct study, a decreasing gradient of risk existed
across BMI categories (normal weight HR: 1.43; 95% CI: 1.14,
1.80; overweight HR: 1.23; 95% CI: 0.99, 1.52; obese HR:
1.11; 95% CI: 0.74, 1.65; P-interaction = 0.026). Further-
more, in the French Prospective Etude Epide´miologique aupre`s
des femmes de la Mutuelle Ge´ne´rale de l’Education Nationale
study, some of whose participants overlapped with those of the
above-mentioned InterAct study, an inverse gradient of risk also
existed across BMI strata (normal weight HR: 2.23; 95% CI:
1.14, 4.36; overweight HR: 2.17; 95% CI: 1.27, 3.68; obese
HR: 1.00; 95% CI: 0.52, 1.92).
The presence of this apparent heterogeneity could be
explained through one or more mechanisms. Our findings do not
support the contention that greater ASB consumption may
contribute to higher overall caloric intake due to overcompen-
sating the perceived ‘‘calories averted’’ by substituting ASBs for
sugar-sweetened beverages with other foods, as our associations
in the normal-weight stratum did not change substantially after
adjustment for total energy intake (26). Nor do they support the
suggestion that ASBs may increase desire to consume sweetened
or energy-dense foods (27, 28), as adjusting our models for
consumption of energy-dense food items (e.g., fat intake) did not
alter our associations (data not shown).
Recently, appreciation has increased of a potential role of
alterations of the gut microbiome in mediating the risk of
various conditions, including metabolic dysfunction, obesity,
and glucose intolerance (29–31). Suez et al. (3) reported that
consumption of noncaloric artificial sweeteners (saccharin,
sucralose, aspartame) in mice induces glucose intolerance
TABLE 4 Adjusted mean changes in measures of glucose homeostasis associated with a 1-unit increase in daily ASB consumption,
stratified by BMI: ELSA-Brasil (2008–2010), n = 12,8841
BMI ,25 kg/m2 (n = 4998) BMI $25 to ,30 kg/m2 (n = 5185) BMI $30 kg/m2 (n = 2701)
For a one unit change
in frequency of ASB
consumption/d P value
For a one unit change
in frequency of ASB
consumption/d P value
For a one unit change
in frequency of ASB
consumption/d P value
Fasting glucose, mg/dL
Model 1 0.48 6 0.14 0.001 0.10 6 0.14 0.46 20.06 6 0.22 0.80
Model 2 0.43 6 0.17 0.01 0.17 6 0.17 0.30 0.25 6 0.26 0.32
2-h postload glucose, mg/dL
Model 1 0.48 6 0.38 0.22 20.47 6 0.37 0.21 20.61 6 0.55 0.27
Model 2 20.11 6 0.43 0.80 20.64 6 0.43 0.14 20.70 6 0.66 0.28
HbA1c, %
Model 1 0.020 6 0.006 0.001 0.004 6 0.006 0.51 0.006 6 0.008 0.48
Model 2 0.021 6 0.007 0.004 0.015 6 0.007 0.03 20.002 6 0.010 0.82
HOMA-IR
Model 1 0.04 6 0.01 0.002 20.02 6 0.02 0.28 20.09 6 0.03 0.002
Model 2 0.03 6 0.01 0.01 20.03 6 0.02 0.19 20.07 6 0.03 0.03
HOMA-b, %
Model 1 20.68 6 0.25 0.007 20.10 6 0.30 0.74 20.54 6 0.51 0.29
Model 2 20.77 6 0.29 0.009 20.06 6 0.35 0.86 21.10 6 0.62 0.08
ISI-composite
Model 1 20.17 6 0.09 0.07 0.11 6 0.06 0.05 0.20 6 0.04 ,0.0001
Model 2 20.03 6 0.10 0.74 0.14 6 0.06 0.02 0.19 6 0.05 0.0002
1 Values are mean changes6 SEs. Adjusted through multiple linear regression with the following covariates—model 1: adjusted for sex, age (y), race/skin color, and study center.
Model 2: model 1 plus educational attainment, current smoking status, leisure time physical activity, hypertension, family history of diabetes, dietary changes in previous 6 mo,
alcohol consumption, sugar-sweetened beverage consumption, unsweetened beverage consumption, diet/light food consumption, total energy intake (kcal/d), BMI, and waist-to-
hip ratio. P value represents the test for an association of an increase of one moment of ASB consumption per day with each respective outcome of interest. ASB, artificially
sweetened beverage; ELSA-Brasil, Estudo Longitudinal de Sau´de do Adulto–Brasil; HbA1c, glycated hemoglobin; HOMA-b, homeostasis model assessment of b-cell function;
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; ISI-composite, composite insulin sensitivity index.
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through mechanisms involving alterations of the composition
and function of intestinal microbiota. In lean mice, these
changes in microbiota were linked to major increases in glycan
degradation pathways, resulting in the synthesis of various
compounds, including SCFAs. Specifically, the investigators
report elevated concentrations of propionate and acetate in
saccharin-consuming mice, which can act as substrates for
gluconeogenesis in the liver (32). Consequently, our findings of a
greater association for fasting than for 2-h blood glucose are
consistent with these findings in rodents that ASB-mediated
effects may be driven by mechanisms operating mostly in the
fasting state. Gut-derived metabolites have also been suggested
to alter b-cell function (33), which could possibly mediate
the decrease in HOMA-b that we found in normal-weight
individuals.
The absence of an association of ASBs with diabetes among
overweight and obese participants is consistent with an inter-
pretation that whatever diabetogenic effect ASBs have is
attenuated among those already within higher BMI ranges. In
addition, the apparent protective effect of ASBs on postprandial
glucose concentrations among the overweight and, to a lesser
extent, the obese could be due to confounding—the reflection of
an increased usage of ASBs in those who are making a successful
effort to reduce caloric intake along with other positive changes
in lifestyle and diet.
The strengths of our study include the use of a standard 75-g
oral-glucose-tolerance test, measurement of glycated hemoglo-
bin, and the assessment of various indicators of insulin resistance
and b-cell function. Around one-fourth of our sample reported
regularly consuming ASBs at least 3 times/d, allowing us to
explore the association of higher ASB consumption amounts
with the prevalence of newly diagnosed diabetes, compared to
previous studies. Furthermore, the large numbers of newly
diagnosed diabetes cases in each of our BMI strata have
provided us with greater statistical power to detect the reported
differential associations across these strata. Last, by collecting
data on the addition of artificial sweetener to several beverages,
we were able to provide a more comprehensive analysis of the
influence of ASB consumption on diabetes risk than previous
studies, which have mainly been limited to artificially sweetened
soda consumption or coffee. In this regard, our finding that
an ASB-diabetes association in normal-weight individuals was
present when coffee was the main ASB was possible given the
widespread consumption of sweetened coffee in Brazil.
Some limitations of this study deserve mention. The study
was cross-sectional, limiting interpretation with regard to causal
direction of associations. However, it is less likely that individ-
uals, such as our cases, without knowledge of their diabetes
status, would alter their ASB consumption on the basis of
symptoms or disease. The food-frequency questionnaire has a
large measurement error; however, this would most likely
lead to an underestimate of the increased odds we found.
ELSA-Brasil did not ascertain the type of artificial sweetener
used. But in this regard, sweeteners most commonly used
internationally, including saccharin, sucralose, and aspartame,
are all marketed in Brazil. That no association in normal-weight
individuals was found between newly diagnosed diabetes and
greater consumption of ‘‘diet’’ or ‘‘low-calorie’’ foods might be
considered an inconsistency. However, although these foods
frequently contain artificial sweeteners, they also frequently do
not (e.g., ‘‘low-fat’’ or ‘‘low-sodium’’ foods) and were not
ascertained in ELSA in a manner permitting distinction in this
regard. Last, although attempts were made to statistically adjust
for possible confounding variables in our data set, we cannot
rule out the possibility of residual or unknown confounding in
our analyses.
In summary, although no overall association between ASB
consumption and newly diagnosed diabetes was present, greater
consumption of ASBs was associated with a greater prevalence
of newly diagnosed diabetes in normal-weight individuals. This
association does not place into question the use of ASBs in the
overweight or obese, in whom we found, in fact, some improve-
ment in postload blood glucose concentrations and measures of
insulin resistance, or in those with previously diagnosed diabe-
tes, since they were excluded from the analyses. However, our
findings do raise the question of ASB use in a large fraction of
the population. In light of these findings, further prospective
investigation of ASB use in normal-weight individuals is necessary
to document their safety.
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